Developer docs
API playgroundTry for free, no card

Search company profiles

Molecular Assemblies

Full company profile

uuid0000vbi

Namestring
Molecular Assemblies
Legal namestring
Molecular Assemblies, Inc.
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Molecular Assemblies was a privately held San Diego-based life-sciences tools company founded in 2013 that developed Fully Enzymatic Synthesis (FES)™, a proprietary enzymatic DNA synthesis technology designed as an alternative to traditional phosphoramidite chemistry. The core technical claim was a 99.9% step-wise incorporation efficiency versus the ~99.6% plateau of chemical synthesis, achieved through a terminal deoxynucleotidyl transferase-based process that operates at up to 70 °C and neutral pH. These conditions allow the platform to synthesize long, high-purity single-stranded oligonucleotides up to 400 bases, including traditionally difficult sequences with high or low GC content, long homopolymer stretches, and repetitive elements, without the need for post-synthesis PAGE or HPLC purification. The modular manufacturing platform was positioned to deliver faster order-to-shipment turnaround with predictable first-time pass rates.

The company targeted an enterprise B2B customer base across four primary use-case segments: therapeutics and vaccines, synthetic biology and genomics, agriculture and food, and DNA-based data storage. It sold DNA synthesis services and oligonucleotide products via direct field sales and its website (with a "Get Long Oligos Now" call-to-action), operating on a quote-based, non-publicly-disclosed pricing model. It carried no named enterprise customers and no disclosed revenue, indicating that commercial activity was nascent through its independent life. Molecular Assemblies was venture-backed, raising cumulative equity, grant, and corporate funding exceeding $60 million across rounds from 2013 through 2024, with a $25.8 million Series B in March 2022 representing the largest disclosed equity round. Strategic investors and partners included Agilent Technologies, Codexis, Casdin Capital, Alexandria Venture Investments, Argonautic Ventures, iSelect Fund, LYFE Capital, Keshif Ventures, and DCVC, alongside non-dilutive capital from the NIH (SBIR), NSF, and DARPA/GE Healthcare.

In January 2025, Molecular Assemblies' property and intellectual property were acquired by Maravai LifeSciences and integrated into TriLink BioTechnologies, ending independent operations. The technology continues to be offered under the Molecular Assemblies brand within TriLink's commercial portfolio.

Short descriptiontext

Molecular Assemblies was a San Diego-based life-sciences tools company that developed proprietary Fully Enzymatic Synthesis (FES)™ enzymatic DNA synthesis technology to produce long, high-purity oligonucleotides up to 400 bases for enterprise customers in therapeutics, synthetic biology, agriculture, and data storage, and was acquired by Maravai LifeSciences/TriLink BioTechnologies in January 2025.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
enzymatic DNA synthesis, oligonucleotide manufacturing, synthetic biology tools, nucleic acid production, long oligo synthesis
Industry1 code
PRIMARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
DNA Synthesis Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1DNA Synthesis Services/Products
TypeOne Time License
Description

Molecular Assemblies produces and sells long, pure, and accurate DNA oligonucleotides synthesized using their proprietary Fully Enzymatic Synthesis technology. The modular manufacturing platform enables fast order-to-shipment turnaround times.

go.trilinkbiotech.com
Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Molecular Assemblies developed and sold long, pure, and accurate single-stranded DNA oligonucleotides produced through its proprietary Fully Enzymatic Synthesis (FES)™ enzymatic technology. The platform synthesizes DNA up to 400 bases in length at 99.9% step-wise incorporation efficiency, operating at temperatures up to 70°C and neutral pH without requiring post-synthesis PAGE or HPLC purification. The offering targeted enterprise customers in therapeutics/vaccines, immunotherapy, agriculture, and nanotechnology applications requiring high-quality, long DNA sequences.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 99.9% step-wise incorporation efficiency (vs 99.6% for chemical synthesis)
+2 more records
Product overview1 text field

Molecular Assemblies offered Fully Enzymatic Synthesis (FES)™ technology, a proprietary enzymatic DNA synthesis platform that produces long, pure, and accurate single-stranded DNA oligonucleotides up to 400 bases. The core technology operates at 99.9% step-wise incorporation efficiency (versus 99.6% for traditional chemical synthesis), using a neutral pH enzymatic process at up to 70°C that eliminates the need for post-synthesis PAGE or HPLC purification. The company targeted multiple application segments including therapeutics/vaccines, immunotherapy, agriculture, and nanotechnology. Following Maravai LifeSciences' acquisition in January 2025, the assets and IP were integrated into TriLink BioTechnologies, with the technology now offered as part of TriLink's product portfolio under the Molecular Assemblies brand.

Product and service2 records
1Fully Enzymatic Synthesis (FES)™ DNA Synthesis Platform
CategoryDNA synthesis platform
Description

Proprietary enzymatic DNA synthesis platform that achieves 99.9% step-wise incorporation efficiency versus 99.6% for traditional chemical synthesis, enabling production of long, pure, and accurate DNA oligos up to 400 bases without the need for post-synthesis PAGE or HPLC purification. Sold to enterprise customers in therapeutics, vaccines, immunotherapy, agriculture, and synthetic biology.

2Long Single-Stranded Oligonucleotides
CategoryCustom DNA oligo products
Description

DNA oligonucleotides produced using FES technology reaching up to 400 bases in length with high accuracy and purity through in-process purification; operates at up to 70°C to handle difficult secondary structures including high/low GC content, long homopolymer stretches, and repetitive elements. Offered as a custom synthesis product to enterprise customers.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMajorTypeOthersAnnounced on2025-01-01
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1DNA Script
TypeDirect peer
Description

DNA Script is the most direct competitor — also developing enzymatic DNA synthesis technology (Syntax platform) targeting long, high-fidelity oligonucleotides for similar applications in synthetic biology, therapeutics, and genomics. Both companies share the same core technical premise of replacing phosphoramidite chemistry with terminal deoxynucleotidyl transferase-based enzymatic synthesis.

TypeDirect peer
Description

Twist Bioscience is a leading DNA synthesis provider using silicon-based high-throughput chemical synthesis, directly competing with Molecular Assemblies in gene fragments, oligo pools, and synthetic biology tools. Twist serves overlapping customer segments (therapeutics, ag-bio, data storage) and represents the dominant incumbent that FES technology seeks to disrupt.

TypeEmerging player
Description

Ansa Bio is an emerging player in enzymatic DNA synthesis, developing a polymerase-based platform for long, accurate oligonucleotides. It targets the same customer base as Molecular Assemblies in synthetic biology and therapeutics and represents a parallel technology approach to enzymatic synthesis.

TypeBroad incumbent
Description

IDT is a long-established incumbent in custom oligonucleotide synthesis, acquired by Danaher. It serves the same therapeutic and research customers with a broad portfolio of chemically synthesized oligos, representing both a major competitor and a potential strategic acquirer in the same space.

TypeBroad incumbent
Description

GenScript is a major life sciences services provider with significant gene synthesis and oligo manufacturing capabilities. It serves overlapping synthetic biology and therapeutic customers globally and competes across the DNA synthesis value chain.

TypeBroad incumbent
Description

Eurofins Genomics operates one of the largest commercial DNA oligonucleotide synthesis operations globally, serving research, diagnostic, and therapeutic customers. It is a broad incumbent with significant scale in chemically synthesized oligos.

TypeDirect peer
Description

Synbio Technologies is a gene synthesis and oligo provider serving synthetic biology and therapeutics customers with chemical and emerging enzymatic methods. It competes in gene fragment and long oligo delivery directly with Molecular Assemblies' offering.

TypeOthers
Description

Codexis is a protein engineering company and Molecular Assemblies' investor (via SynBio Innovation Accelerator). It is an enabling/partner company providing enzyme engineering capabilities relevant to enzymatic DNA synthesis and represents an adjacent technology platform.

TypeEmerging player
Description

Catalog Technologies is a DNA data storage company that depends on long, high-fidelity oligonucleotide synthesis — directly aligned with one of Molecular Assemblies' targeted applications. It serves as both a potential customer and adjacent player in the DNA-based data storage value chain.

TypeOthers
Description

TriLink BioTechnologies acquired Molecular Assemblies' IP and assets in January 2025 and now commercializes the FES technology under the Molecular Assemblies brand. It is an enabling platform/integrator that serves the same customer base as a nucleic acid manufacturing partner.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors20 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Molecular Assemblies

DNA Synthesis Servicesmolecularassemblies.com

Molecular Assemblies was a San Diego-based life-sciences tools company that developed proprietary Fully Enzymatic Synthesis (FES)™ enzymatic DNA synthesis technology to produce long, high-purity oligonucleotides up to 400 bases for enterprise customers in therapeutics, synthetic biology, agriculture, and data storage, and was acquired by Maravai LifeSciences/TriLink BioTechnologies in January 2025.

What Molecular Assemblies does

Molecular Assemblies was a privately held San Diego-based life-sciences tools company founded in 2013 that developed Fully Enzymatic Synthesis (FES)™, a proprietary enzymatic DNA synthesis technology designed as an alternative to traditional phosphoramidite chemistry. The core technical claim was a 99.9% step-wise incorporation efficiency versus the ~99.6% plateau of chemical synthesis, achieved through a terminal deoxynucleotidyl transferase-based process that operates at up to 70 °C and neutral pH. These conditions allow the platform to synthesize long, high-purity single-stranded oligonucleotides up to 400 bases, including traditionally difficult sequences with high or low GC content, long homopolymer stretches, and repetitive elements, without the need for post-synthesis PAGE or HPLC purification. The modular manufacturing platform was positioned to deliver faster order-to-shipment turnaround with predictable first-time pass rates.

The company targeted an enterprise B2B customer base across four primary use-case segments: therapeutics and vaccines, synthetic biology and genomics, agriculture and food, and DNA-based data storage. It sold DNA synthesis services and oligonucleotide products via direct field sales and its website (with a "Get Long Oligos Now" call-to-action), operating on a quote-based, non-publicly-disclosed pricing model. It carried no named enterprise customers and no disclosed revenue, indicating that commercial activity was nascent through its independent life. Molecular Assemblies was venture-backed, raising cumulative equity, grant, and corporate funding exceeding $60 million across rounds from 2013 through 2024, with a $25.8 million Series B in March 2022 representing the largest disclosed equity round. Strategic investors and partners included Agilent Technologies, Codexis, Casdin Capital, Alexandria Venture Investments, Argonautic Ventures, iSelect Fund, LYFE Capital, Keshif Ventures, and DCVC, alongside non-dilutive capital from the NIH (SBIR), NSF, and DARPA/GE Healthcare.

In January 2025, Molecular Assemblies' property and intellectual property were acquired by Maravai LifeSciences and integrated into TriLink BioTechnologies, ending independent operations. The technology continues to be offered under the Molecular Assemblies brand within TriLink's commercial portfolio.

Molecular Assemblies firmographics

Firmographics
Name
Molecular Assemblies
Legal name
Molecular Assemblies, Inc.
Website
https://molecularassemblies.com
Company type
Private
Founded year
2013
Operating status
Acquired
Headcount range
1–10 employees
Short description
Molecular Assemblies was a San Diego-based life-sciences tools company that developed proprietary Fully Enzymatic Synthesis (FES)™ enzymatic DNA synthesis technology to produce long, high-purity oligonucleotides up to 400 bases for enterprise customers in therapeutics, synthetic biology, agriculture, and data storage, and was acquired by Maravai LifeSciences/TriLink BioTechnologies in January 2025.
Ownership category
akta.pro rank

Molecular Assemblies industry classification

Industry
Product category
DNA Synthesis Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Enzymatic DNA synthesis
  • Oligonucleotide manufacturing
  • Synthetic biology tools
  • Nucleic acid production
  • Long oligo synthesis

Where Molecular Assemblies is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Molecular Assemblies business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. DNA Synthesis Services/Products: Molecular Assemblies produces and sells long, pure, and accurate DNA oligonucleotides synthesized using their proprietary Fully Enzymatic Synthesis technology. The modular manufacturing platform enables fast order-to-shipment turnaround times.

Go-to-market motion1 record

Distribution channels1 record

Molecular Assemblies product offering

Product offering

Core offering

Molecular Assemblies developed and sold long, pure, and accurate single-stranded DNA oligonucleotides produced through its proprietary Fully Enzymatic Synthesis (FES)™ enzymatic technology. The platform synthesizes DNA up to 400 bases in length at 99.9% step-wise incorporation efficiency, operating at temperatures up to 70°C and neutral pH without requiring post-synthesis PAGE or HPLC purification. The offering targeted enterprise customers in therapeutics/vaccines, immunotherapy, agriculture, and nanotechnology applications requiring high-quality, long DNA sequences.

Product overview

Molecular Assemblies offered Fully Enzymatic Synthesis (FES)™ technology, a proprietary enzymatic DNA synthesis platform that produces long, pure, and accurate single-stranded DNA oligonucleotides up to 400 bases. The core technology operates at 99.9% step-wise incorporation efficiency (versus 99.6% for traditional chemical synthesis), using a neutral pH enzymatic process at up to 70°C that eliminates the need for post-synthesis PAGE or HPLC purification. The company targeted multiple application segments including therapeutics/vaccines, immunotherapy, agriculture, and nanotechnology. Following Maravai LifeSciences' acquisition in January 2025, the assets and IP were integrated into TriLink BioTechnologies, with the technology now offered as part of TriLink's product portfolio under the Molecular Assemblies brand.

Differentiator

Problem solved

Functional benefit

Products and services

  • Fully Enzymatic Synthesis (FES)™ DNA Synthesis Platform Proprietary enzymatic DNA synthesis platform that achieves 99.9% step-wise incorporation efficiency versus 99.6% for traditional chemical synthesis, enabling production of long, pure, and accurate DNA oligos up to 400 bases without the need for post-synthesis PAGE or HPLC purification. Sold to enterprise customers in therapeutics, vaccines, immunotherapy, agriculture, and synthetic biology.
  • Long Single-Stranded Oligonucleotides DNA oligonucleotides produced using FES technology reaching up to 400 bases in length with high accuracy and purity through in-process purification; operates at up to 70°C to handle difficult secondary structures including high/low GC content, long homopolymer stretches, and repetitive elements. Offered as a custom synthesis product to enterprise customers.

Quantifiable outcome

  • 99.9% step-wise incorporation efficiency (vs 99.6% for chemical synthesis)
  • +2 more outcomes

Companies that use Molecular Assemblies

Customer profile

Segments4 records

Ideal customer profiles3 records

Molecular Assemblies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Molecular Assemblies partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Molecular Assemblies competitors and assessment

Company assessment

Direct peers

  • DNA Script: DNA Script is the most direct competitor — also developing enzymatic DNA synthesis technology (Syntax platform) targeting long, high-fidelity oligonucleotides for similar applications in synthetic biology, therapeutics, and genomics. Both companies share the same core technical premise of replacing phosphoramidite chemistry with terminal deoxynucleotidyl transferase-based enzymatic synthesis.
  • Twist Bioscience: Twist Bioscience is a leading DNA synthesis provider using silicon-based high-throughput chemical synthesis, directly competing with Molecular Assemblies in gene fragments, oligo pools, and synthetic biology tools. Twist serves overlapping customer segments (therapeutics, ag-bio, data storage) and represents the dominant incumbent that FES technology seeks to disrupt.
  • Synbio Technologies: Synbio Technologies is a gene synthesis and oligo provider serving synthetic biology and therapeutics customers with chemical and emerging enzymatic methods. It competes in gene fragment and long oligo delivery directly with Molecular Assemblies' offering.

Emerging players

  • Ansa Bio: Ansa Bio is an emerging player in enzymatic DNA synthesis, developing a polymerase-based platform for long, accurate oligonucleotides. It targets the same customer base as Molecular Assemblies in synthetic biology and therapeutics and represents a parallel technology approach to enzymatic synthesis.
  • Catalog Technologies: Catalog Technologies is a DNA data storage company that depends on long, high-fidelity oligonucleotide synthesis — directly aligned with one of Molecular Assemblies' targeted applications. It serves as both a potential customer and adjacent player in the DNA-based data storage value chain.

Broad incumbents

  • Integrated DNA Technologies (IDT): IDT is a long-established incumbent in custom oligonucleotide synthesis, acquired by Danaher. It serves the same therapeutic and research customers with a broad portfolio of chemically synthesized oligos, representing both a major competitor and a potential strategic acquirer in the same space.
  • GenScript: GenScript is a major life sciences services provider with significant gene synthesis and oligo manufacturing capabilities. It serves overlapping synthetic biology and therapeutic customers globally and competes across the DNA synthesis value chain.
  • Eurofins Genomics: Eurofins Genomics operates one of the largest commercial DNA oligonucleotide synthesis operations globally, serving research, diagnostic, and therapeutic customers. It is a broad incumbent with significant scale in chemically synthesized oligos.

Others

  • Codexis: Codexis is a protein engineering company and Molecular Assemblies' investor (via SynBio Innovation Accelerator). It is an enabling/partner company providing enzyme engineering capabilities relevant to enzymatic DNA synthesis and represents an adjacent technology platform.
  • TriLink BioTechnologies: TriLink BioTechnologies acquired Molecular Assemblies' IP and assets in January 2025 and now commercializes the FES technology under the Molecular Assemblies brand. It is an enabling platform/integrator that serves the same customer base as a nucleic acid manufacturing partner.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks7 records

Key highlights5 records

Customer concentration

Molecular Assemblies social profiles

Digital presence

Molecular Assemblies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Molecular Assemblies leadership team

Management profile

Number of profiles

Profiles6 records

Molecular Assemblies funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors20 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Molecular Assemblies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Molecular Assemblies

What does Molecular Assemblies do?

Molecular Assemblies developed and sold long, pure, and accurate single-stranded DNA oligonucleotides produced through its proprietary Fully Enzymatic Synthesis (FES)™ enzymatic technology. The platform synthesizes DNA up to 400 bases in length at 99.9% step-wise incorporation efficiency, operating at temperatures up to 70°C and neutral pH without requiring post-synthesis PAGE or HPLC purification. The offering targeted enterprise customers in therapeutics/vaccines, immunotherapy, agriculture, and nanotechnology applications requiring high-quality, long DNA sequences.

Is Molecular Assemblies a public or private company?

Molecular Assemblies is a private company. It is classified as venture growth investor backed and is currently acquired.

When was Molecular Assemblies founded?

Molecular Assemblies was founded in 2013. It employs 1 to 10 people.

Where is Molecular Assemblies based?

Molecular Assemblies is headquartered in San Diego, United States, in the North America region.

How does Molecular Assemblies make money?

One revenue line is on record: DNA Synthesis Services/Products.

Who are Molecular Assemblies's main competitors?

Direct peers on record are DNA Script, Twist Bioscience and Synbio Technologies. Emerging players are Ansa Bio and Catalog Technologies. Broad incumbents are Integrated DNA Technologies (IDT), GenScript and Eurofins Genomics. Others are Codexis and TriLink BioTechnologies.

Does Molecular Assemblies have an API?

No public API is recorded for Molecular Assemblies.

What industry is Molecular Assemblies in?

Molecular Assemblies's product category is DNA Synthesis Services. Its primary akta.pro industry code is HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireDNA Synthesis Market to Reach $30.4 billion, Globally, by 2035 at 18.2% CAGR: Allied Market ResearchThe DNA synthesis market is projected to grow from $5.7 billion in 2025 to $30.4 billion by 2035, a CAGR of 18.2%. North America held the largest share in 2025, while Asia-Pacific is expected to see the highest growth rate.Precedence ResearchOligonucleotides Market Size to Hit USD 14.54 Billion by 2034The global oligonucleotides market is projected to grow from USD 4.79 billion in 2025 to USD 14.54 billion by 2034, expanding at a CAGR of 13.14%, driven by rising demand for precision medicine, gene therapies, and molecular diagnostics. North America dominated the market in 2024, while Asia Pacific is expected to witness the fastest growth through 2034. Key recent developments include Maravai LifeSciences' acquisition of Molecular Assemblies' property and intellectual property in January 2025, and Co-Dx with CoSara Diagnostics commissioning an oligonucleotide synthesis facility in India in December 2024.openPR.comDNA nanotechnology Market Future Business Opportunities 2025-2032 | BioNano Systems Ltd., Molecular AssembliesThe global DNA nanotechnology market was valued at US$4.4 billion in 2025 and is projected to reach US$21.23 billion by 2032, a CAGR of 25.2%. Growth is driven by applications in drug delivery, biosensing, and nanoelectronics, with pharmaceuticals accounting for about 35% of revenue in 2024.Business Wire BlogMaravai LifeSciences Acquires Assets and Intellectual Property from Molecular AssembliesMaravai LifeSciences acquired intellectual property and assets from Molecular Assemblies, including its Fully Enzymatic Synthesis technology for mRNA and oligonucleotide manufacturing. The acquisition aims to expand TriLink's capabilities and lower costs by vertically integrating NTPs and enzymes. Maravai plans to enhance workflows to push oligo length and purity limits.PR NewswireMolecular Assemblies Achieves Key Milestones in DARPA NOW Project for On-Demand DNA Vaccine ManufacturingMolecular Assemblies secured an additional $4 million in DARPA funding to advance its enzymatic DNA synthesis technology for the NOW project, which is led by GE HealthCare. This investment supports the development of a mobile platform designed to rapidly produce DNA-based vaccines and therapeutics in response to pandemics or bio-threats. The company will utilize its proprietary Fully Enzymatic Synthesis (FES) technology to create high-accuracy therapeutic targets.MolecularassembliesMolecular AssembliesMolecular Assemblies has been acquired by TriLink BioTechnologies, becoming part of the latter organization. The article highlights TriLink's Fully Enzymatic Synthesis (FES) technology, which enables the production of long, pure DNA oligos with high accuracy and faster turnaround times compared to traditional chemical synthesis methods.PR NewswireMolecular Assemblies Announces the Appointment of Two Industry Leaders to Its Commercial-Technology Advisory BoardMolecular Assemblies, Inc. announced the appointment of two industry leaders, David Smoller, Ph.D. and Stephen Turner, Ph.D., to its Commercial-Technology Advisory Board (CTAB). The new board members bring expertise in life science commercialization and nucleic acid technologies to support the company's Fully Enzymatic Synthesis (FES) technology, which produces long, high-quality DNA for applications in therapeutics, diagnostics, and synthetic biology. Todd C. Peterson, Ph.D. continues as CTAB Chair, providing oversight for the company's commercial expansion efforts.PR NewswireGlobal Enzymatic DNA Synthesis Market Report 2023-2028, Featuring Profiles of Telesis Bio, Twist Bioscience ,GenScript Biotech, Evonetix, Camena Bio, Molecular Assemblies, Touchlight and Kern SystemsThe global enzymatic DNA synthesis market was valued at US$253.42 million in 2022 and is projected to reach US$2.11 billion by 2028, a CAGR of 42.43%. DNA library synthesis held the largest segment share in 2022, driven by genomics research demand.ForbesSynthetic Biology Startup Molecular Assemblies Ships First DNA From New San Diego FacilityMolecular Assemblies shipped its first enzymatically synthesized DNA oligos to customers from a new San Diego facility. The company's proprietary FES technology enables longer, purer DNA without the length limits of chemical synthesis. CEO Mike Kamdar said the company will scale up to unrestricted release later this year.NatureDNA synthesis technologies to close the gene writing gapThe review examines DNA synthesis technologies, including molecular assembly, enzymatic methods, and microarray techniques, to address the gap between reading and writing DNA. It highlights that synthesizing sequences over 200 bp remains unaffordable and discusses commercialization, regulatory oversight, and business models.